Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Oct 28;101(10):adv00581.
doi: 10.2340/actadv.v101.545.

Rapid Enlargement of Vitiligo Vulgaris after Initiation of Dupilumab for Atopic Dermatitis: A Case Report

Shintaro Takeoka, Masahiro Kamata  1 , Ikumi Yokoi, Aya Takehara, Yayoi Tada
Affiliations
Case Reports

Rapid Enlargement of Vitiligo Vulgaris after Initiation of Dupilumab for Atopic Dermatitis: A Case Report

Shintaro Takeoka et al. Acta Derm Venereol. .
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Skin manifestations of vitiligo vulgaris and atopic dermatitis. (A) Before, (B) 3 months after, and (C) 6 months after initiation of dupilumab. Yellow arrows show the area of leukoderma. Red arrows show grey hair.
See this image and copyright information in PMC

References

    1. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. . Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375: 2335–2348. - PubMed
    1. Uchida H, Kamata M, Mizukawa I, Watanabe A, Agematsu A, Nagata M, et al. . Real-world effectiveness and safety of dupilumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study. Br J Dermatol 2019; 181: 1083–1085. - PubMed
    1. Uchida H, Kamata M, Kato A, Mizukawa I, Watanabe A, Agematsu A, et al. . One-year real-world clinical effectiveness, safety, and laboratory safety of dupilumab in Japanese adult patients with atopic dermatitis: a single-center retrospective study. J Am Acad Dermatol 2021; 84: 547–550. - PubMed
    1. Wańkowicz-Kalińska A, van den Wijngaard RM, Tigges BJ, Westerhof W, Ogg GS, Cerundolo V, et al. . Immunopolarization of CD4+ and CD8+ T cells to type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest 2003; 83: 683–695. - PubMed
    1. Yang L, Wei Y, Sun Y, Shi W, Yang J, Zhu L, et al. . Interferongamma inhibits melanogenesis and induces apoptosis in melanocytes: a pivotal role of CD8+ cytotoxic t lymphocytes in vitiligo. Acta Derm Venereol 2015; 95: 664–670. - PubMed

Publication types

MeSH terms

Substances